These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15105150)

  • 1. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.
    Farrell DJ; Felmingham D
    Antimicrob Agents Chemother; 2004 May; 48(5):1882-4. PubMed ID: 15105150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.
    Jorgensen JH; Crawford SA; McElmeel ML; Whitney CG
    Antimicrob Agents Chemother; 2004 Feb; 48(2):605-7. PubMed ID: 14742216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.
    Schito GC; Marchese A; Elkharrat D; Farrell DJ;
    J Chemother; 2004 Feb; 16(1):13-22. PubMed ID: 15077994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
    Felmingham D; Reinert RR; Hirakata Y; Rodloff A
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():25-37. PubMed ID: 12239226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.
    Jenkins SG; Farrell DJ; Patel M; Lavin BS
    J Infect; 2005 Dec; 51(5):355-63. PubMed ID: 15950288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
    Farrell DJ; Jenkins SG
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i17-22. PubMed ID: 15265832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.
    Farrell DJ; Morrissey I; Bakker S; Buckridge S; Felmingham D
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3169-71. PubMed ID: 15273142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.
    Hsueh PR; Teng LJ; Wu TL; Yang D; Huang WK; Shyr JM; Chuang YC; Wan JH; Yan JJ; Lu JJ; Wu JJ; Ko WC; Chang FY; Yang YC; Lau YJ; Liu YC; Lee CM; Leu HS; Liu CY; Luh KT;
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2145-51. PubMed ID: 12821460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A; Koncan R; Bahar G; Cornaglia G
    J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.
    Kresken M; Henrichfreise B; Bagel S; Brauers J; Wiedemann B
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3193-5. PubMed ID: 15273149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).
    Schito GC; Felmingham D
    Int J Antimicrob Agents; 2005 Dec; 26(6):479-85. PubMed ID: 16289710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
    Farrell DJ; Morrissey I; Bakker S; Felmingham D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():39-47. PubMed ID: 12239227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.
    Morosini MI; Cantón R; Loza E; Negri MC; Galán JC; Almaraz F; Baquero F
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2427-31. PubMed ID: 11502509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.
    Reinert RR; van der Linden M; Al-Lahham A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3520-2. PubMed ID: 16048973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.
    Al-Lahham A; Appelbaum PC; van der Linden M; Reinert RR
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3897-900. PubMed ID: 17065627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrolide-resistance mechanisms in Streptococcus pneumoniae isolates from Belgium.
    Van Eldere J; Meekers E; Lagrou K; Massonet C; Canu A; Devenyns I; Verhaegen J; Syrogiannopoulos G; Leclercq R
    Clin Microbiol Infect; 2005 Apr; 11(4):332-4. PubMed ID: 15760433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.